Uterine cancer at a glance

Among gynecological tumors, malignant uterine tumor (MUT) is the 6th most common cancer in women and the 15th most common cancer overall. There were approximately 382 069 new cases and 89 929 deaths attributed to this type worldwide in 2018. Therefore, MUT was the second most common gynecological cancer and the fourth leading cause of death due to gynecological cancer in 2018, and is expected to increase the incidence rate by more than 50% globally by 2040. Mortality rates are lowest in Central and South Asia and most of Africa. Survivors of MUT may experience treatment- related issues, including infertility, early onset of menopause, sexual problems, and lower limb lymphedema. WHO builds its own database from national modeling incidence estimates, using incidence ratios with a sampling method that relies on the calculation of a weighted or simple average of the most popular local rates applied to the population of a few regions or by an approximate estimate based on data provided by health establishments in neighboring countries. While in Algeria, existing statistical and epidemiological data and updated information on the pathology are insuffi cient. The objective of this work is to highlight the importance and the situation of the MUT in this country and to describe the different recent aspects (etiology, diagnostics and treatment) related to the disease.

1. Taylan E., Oktay K. (2019). Fertility preservation in gynecologic cancers. Gynecol. Oncol., 155 (3), 522–529. doi: 10.1016/j.ygyno.2019.09.012.

2. Bray F., Ferlay J., Soerjomataram I. et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer. J. Clin., 68 (6), 394–424.

3. Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. A Summary of the Third Expert Report. Continous Update Project. 2018. 112 p.

4. Ferlay J., Soerjomataram I., Dikshit R. et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer., 136 (5), E359–E386.

5. Torre L.A., Farhad I., Siegel R.L., Ward E.M., Ahmedin J. (2017). Global cancer in women: burden and trends. Cancer Epidemiol. Biomarkers Prev., 26 (4), 444–457.

6. Zhang S., Gong T.T., Liu F.H. et al. (2019). Global, Regional, and National Burden of Endometrial Cancer, 1990–2017: Results from the Global Burden of Disease Study, 2017. Front. Oncol., 9, 1440. doi: 10.3389/fonc.2019.01440.

7. Hamdi Cherif M., Bidoli E., Birri S. et al. (2015). Cancer estimation of incidence and survival in Algeria 2014. J. Cancer. Res. Ther., 3 (9), 100–104.

8. Wild C.P., Weiderpass E., Stewart B.W. (eds.). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France, 2020. Retrieved June 10, 2021 from http://publications.iarc.fr/586.

9. Global Cancer Observatory. 2018. Retrieved June 10, 2021 from https://gco.iarc.fr.

10. Institut National de Santé Publique. 2019. Retrieved June 10, 2021 from http://www.insp.dz/index.php/publications/registres-des-tumeurs-d-alger.html.

11. Gospodarowicz M., Benedet L., Hutter R.V. et al. (1998). History and international developments in cancer staging. Cancer Prev. Control., 2 (6), 262–268.

12. Benedet J.L. (2006). History of the Annual Report. Int. J. Gynecol. Obstet., 95 (1), S1–S2.

13. Denoix P.F., Schwartz D. (1959). General rules for classifi cation of cancers and presentation of the therapeutic results. Mem. Acad. Chir., 85, 415–424. In French.

14. Kottmeier H.L. Annual Report on the Results of Treatment in Gynecological Cancer. FIGO, 1982.

15. Wittekind C., Greene F.L., Hutter R.V.P., Klimpfi nger M., Sobin L.H. TNM Atlas. Guide Illustré de la Classifi cation TNM/pTNM des Tumeurs Malignes. 5th ed. Springer, 2005. In French.

16. Carcopino X., Levêque J., Riethmuller D. Cancers Gynécologiques Pelviens. Elsevier Masson, 2013. 460 p.

17. Suarez A.A., Felix A.S., Cohn D.E. (2017). Bokhman redux: Endometrial cancer “types” in the 21st century. Gynecol. Oncol., 144 (2), 243–249. doi: 10.1016/j.ygyno.2016.12.010.

18. Wilczyński M., Danielska J., Wilczyński J. (2016). An update of the classical Bokhman’s dualistic model of endometrial cancer. Menopause Rev., 15 (2), 63–68. doi: 10.5114/pm.2016.61186.

19. Just P.A., Borghese B., Alexandre J. (2015). Classifi cation des carcinomes de l’endomètre et de l’ovaire. Cor respondances en Onco-Théranostic, 4 (4), 140–149. In French.

20. Kandoth C., Schultz N., Cherniack A.D. et al. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497 (7447), 67–73.

21. Blair A.R., Casas C.M. (2009). Gynecologic сancers. Prim. Care Clin. Offi ce Pract., 36 (1), 115–130. doi: 10.1016/j.pop.2008.10.001.

22. El-Harrak M. Education thérapeutique des patients atteints de cancer. Thèse de Doctorat en Pharmacie. Univ. Mohamed V. Faculté de médecine et de pharmacie, Rabat, Maroc, 2016. In French.

23. Bats A.S., Rossi L., Le Frere-Belda M.A. et al. (2017). Lynch syndrome and endometrial cancer. Bull. Cancer., 104 (12), 1013–1021.

24. Reid-Nicholson M., Iyengar P., Hummer A.J. et al. (2006). Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Modern Path., 19 (8), 1091–1100.

25. American Cancer Society. Global Cancer Facts & Figures. 4th ed. Atlanta: American Cancer Society, 2018.

26. Jain M.G., Rohan T.E., Howe G.R., Miller A.B. (2000). A cohort study of nutritional factors and endometrial cancer. Eur. J. Epidemiol., 16, 899–905.

27. Collinet P., Poncelet P., Vinatier D. (2008). Cancer de l’endomètre. J. Gynécol. Obstétr. Biol. Reprod., 37 (2), F57–F63.

28. Selbey J.V., Friedman G.D., Herrinton L.J. Pharmaceuticals other than hormones. In D. Schottenfeld, J.F. Fraumeni. Cancer Epidemiology and Prevention (pp. 489–501). New York, Oxford University Press, 1996.

29. Pisani P., Parkin D.M., Muñoz N., Ferlay J. (1997). Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev., 6 (6), 387–400.

30. Baillet. Cours: Cancérologie. Chapitre 3 (2015). Université Pierre et Marie Curie. Faculté de médecine. Service de radiothérapie. Niveau DCEM3. In French.

31. Belhaddad E.H. (2019). La prise en charge du cancer de l’endomètre au CHU Med VI de Marrakech entre 2009 et 2017. Thèse N° 027. Faculté de médecine. Univ. Marrakech. In French.

32. Goodman A. (2018). Endometrial cancer: screening, diagnosis, and surgical staging. In F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment (pp. 13–24). Springer.

33. Anatomie-pathologique. Polycopie (2012). Collège Français des Pathologistes. Ch. 1, 7–11.

34. Pautier P., Haie-Meder C. (2013). Les Cancers de l’endomètre. Fondation ARC. Pour la Recherche. Sur le Cancer. 29 p.

35. Merritt M.A., Cramer D.W. (2010). Molecular pathogenesis of endometrial and ovarian cancer. Cancer. Biomark., 9 (1–6), 287–305.

36. Soslow R.A., Oliva E. (2009). Uterine cancer: pathology. In F. Muggia, E. Oliva (eds.). Uterine Cancer: Screening, Diagnosis, and Treatment. Humana Press, Springer Science + Business Media. New York.

37. Allen D.C. (2006). Histopathology Reporting. Guidelines for Surgical Cancer. 2nd ed. Springer, 239–293.

38. Ellenson L.H. (2007). Endometrial carcinoma — molecular genetic aspects / In A. Giordana, A. Bovicelli, R.J. Kurman (eds.) Molecular Pathology of Gynecologic Cancer (pp. 99–108). Humana Press, New Jersey.

39. Buza N. (2021). HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand. Arch. Pathol. Lab. Med., 145 (6), 687–691. doi: 10.5858/arpa.2020-0207-ra.

40. Sutton C. (1997). Hysterectomy: a historical perspective. Baill. Clin. Obstet. Gynaecol., 11 (1), 1–22.

41. Deffi eux X., de Rochambeau B., Ghêne G. et al. (2015). Hysterectomy for benign pathology: Guidelines for clinical practice. J. Gynecol. Obstet. Biol. Reprod. (Paris), 44 (10), 1219–1227.

42. Van der Meij E., Emanuel M.H. (2016). Hystérectomie pour saignement menstruel abondant. 12 (1), 63–69.

43. Agostini A., Bretelle F., Cravello L. et al. (2003). Vaginal hysterectomy in nulliparous women without prolapse: a prospective comparative study. BJOG, 110 (5), 515–518.

44. Balogun O., Lymberis S., Schiff P.B. (2018). Early-stage endometrial cancer: radiation — less may be more. In F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment (pp. 183–200). Springer.

45. Duska L.R. (2018). Primary hormonal therapy of endometrial cancer. In F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment (pp. 151–169). Springer.

46. Musa F. (2018). Treatment of advanced and recurrent carcinoma: chemotherapy. In F. Muggia, A.D. Santin, E. Oliva (eds.) Uterine Cancer: Screening, Diagnosis, and Treatment (pp. 223–234). Springer.

47. Shen L., Hong L., Zhou S., Zhang G., Mai R. (2019). Mutational landscape implicates epithelial-mesenchymal transition gene TGF-β2 mutations for uterine carcinosarcoma after adjuvant tamoxifen therapy for breast carcinoma. Int. J. Clin. Exp. Path., 12 (3), 996–1002.

48. Pant A., Lee I.I., Lu Z. et al. (2012). Inhibition of AKT with the orally active allosteric AKT inhibitor, MK- 2206, sensitizes endometrial cancer cells to progestin. PLoS One, 7 (7), e41593.

49. Konecny G.E., Santos L., Winterhoff B. et al. (2008). HER2 gene amplifi cation and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br. J. Cancer, 100, 89–95.

50. Luz R., Ferreira J., Rocha M., Félix A. (2016). Uterine carcinosarcoma: clinicopathological features and prognostic factors. Acta Médica Portuguesa, 29 (10), 621. In Portuguese.

51. Black J.D., Roque D.M., Gold L.I., Santin A.D. (2018). Future directions and new targets in endometrial cancer. In F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment (pp. 259–271). Springer.

52. Duska L.R., Garrett A., Rueda B.R. et al. (2001). Endometrial cancer in women 40 years old or younger. Gynecol. Oncol., 83 (2), 388–393.

53. Park J.Y., Seong S.J., Kim T.J. et al. (2013). Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet. Gynecol., 121 (1), 136–142.54.

54. Fleming C.A., Heneghan H.M., O’Brien D. et al. (2018). Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br. J. Surg., 105 (9), 1098–1106.